4,004 reports of this reaction
3.1% of all OXALIPLATIN reports
#7 most reported adverse reaction
NEUROPATHY PERIPHERAL is the #7 most commonly reported adverse reaction for OXALIPLATIN, manufactured by Accord Healthcare Inc.. There are 4,004 FDA adverse event reports linking OXALIPLATIN to NEUROPATHY PERIPHERAL. This represents approximately 3.1% of all 127,128 adverse event reports for this drug.
OXALIPLATIN has an overall safety score of 92 out of 100. Patients taking OXALIPLATIN who experience neuropathy peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROPATHY PERIPHERAL is moderately reported among OXALIPLATIN users, representing a notable but not dominant share of adverse events.
In addition to neuropathy peripheral, the following adverse reactions have been reported for OXALIPLATIN:
The following drugs have also been linked to neuropathy peripheral in FDA adverse event reports:
NEUROPATHY PERIPHERAL has been reported as an adverse event in 4,004 FDA reports for OXALIPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROPATHY PERIPHERAL accounts for approximately 3.1% of all adverse event reports for OXALIPLATIN, making it a notable side effect.
If you experience neuropathy peripheral while taking OXALIPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.